SCHEMBL4332381

SCHEMBL4332381

O=C1CN(CSCc2ccccc2)C(=O)N1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.48
CRBN Q96SW2 3/20 0.47
DDB1 Q16531 2/20 0.47
CYP2C19 P33261 2/20 0.41
NPC1 O15118 5/20 0.38
RAB9A P51151 5/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
MAPT P10636 3/20 0.38
GAA P10253 2/20 0.38
MAPK1 P28482 1/20 0.38
DAO P14920 1/20 0.37
NFKB1 P19838 1/20 0.37
CASP3 P42574 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8658916 0.84 DAO (0.40) EPHX2CRBNDDB1CYP2C19SMN1; SMN2
Hydrochloric Acid SCHEMBL8665315 0.83 MAPT (0.37) EPHX2CRBNDDB1NPC1RAB9A
SCHEMBL8658341 0.83 DAO (0.44) MAPTGAAMAPK1DAOALDH1A1
SCHEMBL9850086 0.78 DDB1 (0.69) EPHX2CRBNDDB1CYP2C19GAA
SCHEMBL1011633 0.78 DDB1 (0.69) EPHX2CRBNDDB1CYP2C19GAA
SCHEMBL8663563 0.77 ALDH1A1 (0.48) CYP2C19NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL8667805 0.77 CYP1A2 (0.53) CYP2C19SMN1; SMN2DAOALDH1A1
SCHEMBL8661737 0.77 EPHX2 (0.43) EPHX2CRBNDDB1NPC1RAB9A
SCHEMBL9850110 0.76 DDB1 (0.67) EPHX2CRBNDDB1CYP2C19GAA
SCHEMBL10335076 0.75 DDB1 (0.51) EPHX2CRBNDDB1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2064202-A2 A NEW CRYSTALLINE FORM G OF (5S)-5-[4-(5-CHLORO-PYRIDIN-2-YLOXY)-PIPERIDINE-1-SULFONYL-METHYL]-5-METHYL-IMIDAZOLIDINE-2,4-DIONE (I) AND INTERMEDIATES THEREOF. AstraZeneca AB (SE) 2009-06-03 EP claimed
WO-2007106022-A2 A NEW CRYSTALLINE FORM G OF (5S) -5- [4- (5-CHLORO-PYRIDIN-2- YLOXY) -PIPERIDINE-1-SULFONYLMETHYL] - 5 -METHYL -IMIDAZOLIDINE - 2,4-DIONE (I) AND INTERMEDIATES THEREOF. ASTRAZENECA AB (SE) 2007-09-20 WO claimed
US-7625934-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2009-12-01 US disclosed
US-20080171882-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-07-17 US disclosed
US-5767140-A USEFUL FOR TREATING AIDS SOUTHERN RESEARCH INSTITUTE (US) 1998-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171882-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP14 EPHX2 1178/4885CRBN 4611/4885DDB1 3347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.